INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
[Click here for information about joining the class action] On May 8, 2025, after the market closed, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of 73.7 million. The Company also announced its full fiscal year 2025 total product revenue guidance had been slashed from 475 million to 300 million, a reduction of over 40% at the midpoint. Iovance revealed it w ...